// App-Quantinova.ai

9011 : KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab.

Researchers

Presenter

  • Natasha B. Leighl

Principal Investigators

  • Matthew David Hellmann

  • Rina Hui

  • Enric Carcereny Costa

  • Enriqueta Felip

  • Myung-Ju Ahn

  • Joseph Paul Eder

  • Ani Sarkis Balmanoukian

  • Charu Aggarwal

  • Leora Horn

  • Amita Patnaik

  • Matthew A. Gubens

  • Suresh S. Ramalingam

  • Gregory M. Lubiniecki

  • Jin Zhang

  • Bilal Piperdi

  • Edward B. Garon

Medical Centers

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Westmead Hospital and University of Sydney, Sydney, Australia

  • Catalan Institute of Oncology, Badalona, Spain

  • Vall dHebron University Hospital Institute of Oncology, Barcelona, Spain

  • Yale University, New Haven, CT

  • The Angeles Clinic and Research Institute, Los Angeles, CA

  • Abramson Cancer Center, Philadelphia, PA

  • Vanderbilt-Ingram Cancer Center, Nashville, TN

  • START-South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX

  • University of California, San Francisco, San Francisco, CA

  • Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, GA

  • Merck & Co., Inc., Kenilworth, NJ

  • David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA

Locations

  • United States

  • Canada

  • Spain

  • Australia

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01295827

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved